Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.

Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13679-13684. doi: 10.1073/pnas.1712064115. Epub 2017 Dec 11.

PMID:
29229836
2.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2016 Jan;126(1):402-3. doi: 10.1172/JCI84828. Epub 2015 Nov 23. No abstract available.

3.

Active Immunotherapy of Cancer.

Chodon T, Koya RC, Odunsi K.

Immunol Invest. 2015;44(8):817-36. doi: 10.3109/08820139.2015.1096684. Review.

PMID:
26575466
4.

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A.

BMC Cancer. 2015 May 5;15:356. doi: 10.1186/s12885-015-1377-8.

5.

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.

Sci Transl Med. 2015 Mar 18;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691.

6.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.

Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.

7.

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.

Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A.

Oncoimmunology. 2014 Jun 25;3:e29244. eCollection 2014.

8.

HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.

Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB.

Cancer Res. 2014 Sep 15;74(18):5173-83. doi: 10.1158/0008-5472.CAN-14-0376. Epub 2014 Jul 18.

9.

Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.

Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B.

Cancer Immunol Res. 2014 May;2(5):459-68. doi: 10.1158/2326-6066.CIR-13-0188. Epub 2014 Jan 30.

10.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

11.

CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3359.

12.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

13.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS.

Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.

14.

Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber T, West BL, Bollag G, Ribas A.

Cancer Res. 2014 Jan 1;74(1):153-161. doi: 10.1158/0008-5472.CAN-13-1816. Epub 2013 Nov 18.

15.

Natural killer T cells in advanced melanoma patients treated with tremelimumab.

Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B.

PLoS One. 2013 Oct 22;8(10):e76829. doi: 10.1371/journal.pone.0076829. eCollection 2013.

16.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR.

Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21.

17.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3182. J Clin Invest. 2016 Jan;126(1):402-3.

18.

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J.

J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.

PMID:
23377663
19.

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.

Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS.

J Transl Med. 2012 Jun 19;10:127. doi: 10.1186/1479-5876-10-127.

20.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A.

Cancer Res. 2012 Aug 15;72(16):3928-37. doi: 10.1158/0008-5472.CAN-11-2837. Epub 2012 Jun 12.

21.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

22.

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.

von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A.

Mol Cancer. 2012 Apr 19;11:22.

23.

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS.

Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.

24.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

25.

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: 10.1073/pnas.1115050108. Epub 2011 Nov 28.

26.

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.

Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM.

J Transl Med. 2011 Nov 7;9:192. doi: 10.1186/1479-5876-9-192.

27.

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.

Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR.

Nat Med. 2011 Jun;17(6):738-43. doi: 10.1038/nm.2375. Epub 2011 May 22.

28.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A.

Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.

29.

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.

Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A.

Clin Cancer Res. 2010 Dec 15;16(24):6040-8. doi: 10.1158/1078-0432.CCR-10-1911.

30.

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS.

Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Retraction in: Cancer Res. 2017 Jul 1;77(13):3718.

31.

Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.

Ribas A, Koya RC.

Future Oncol. 2010 Nov;6(11):1671-3. doi: 10.2217/fon.10.137. No abstract available.

32.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

33.

siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.

Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A.

J Invest Dermatol. 2011 Feb;131(2):453-60. doi: 10.1038/jid.2010.310. Epub 2010 Oct 14.

34.

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.

Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A.

PLoS One. 2010 Sep 15;5(9):e12711. doi: 10.1371/journal.pone.0012711.

35.

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A.

J Immunother. 2010 Oct;33(8):759-68. doi: 10.1097/CJI.0b013e3181f1d644.

36.

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA.

PLoS One. 2010 Jul 22;5(7):e11726. doi: 10.1371/journal.pone.0011726.

37.

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. doi: 10.1073/pnas.1008300107. Epub 2010 Jul 12.

38.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B; UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.

Clin Immunol. 2010 Sep;136(3):338-47. doi: 10.1016/j.clim.2010.04.013. Epub 2010 May 23.

39.

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A.

J Transl Med. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39.

40.

Immune rejection in a humanized model of murine prostate cancer.

Schaue D, Koya RC, Liao YP, Ribas A, McBride WH.

Anticancer Res. 2010 Feb;30(2):409-14.

PMID:
20332447
41.

Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses.

Jirmo AC, Koya RC, Sundarasetty BS, Pincha M, Yu GY, Lai M, Bakshi R, Schlaphoff V, Grabowski J, Behrens G, Wedemeyer H, Stripecke R.

Vaccine. 2010 Jan 22;28(4):922-33. doi: 10.1016/j.vaccine.2009.10.150. Epub 2009 Nov 18.

PMID:
19931383
42.

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR.

J Am Chem Soc. 2009 Jul 22;131(28):9695-703. doi: 10.1021/ja9006707.

43.

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.

von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A.

J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.

44.

Immunosensitization with a Bcl-2 small molecule inhibitor.

Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A.

Cancer Immunol Immunother. 2009 May;58(5):699-708. doi: 10.1007/s00262-008-0592-4. Epub 2008 Sep 20.

PMID:
18807035
45.

Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.

Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, Comin-Anduix B, Prins RM, Faure-Kumar E, Rozengurt N, Cui Y, Kasahara N, Stripecke R.

Mol Ther. 2007 Jul;15(7):1390-9. Epub 2007 May 1.

46.

Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.

Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E, Wang HJ, Herschman H, Kasahara N, Stripecke R.

Mol Ther. 2007 May;15(5):971-80. Epub 2007 Mar 20.

47.

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM.

J Immunol. 2006 Jan 1;176(1):157-64.

48.

Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin.

Qiao H, Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, Kuzumaki N.

Neurobiol Aging. 2005 Jun;26(6):849-55.

PMID:
15718043
50.

Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery.

Koya RC, Kasahara N, Favaro PM, Lau R, Ta HQ, Weber JS, Stripecke R.

J Immunother. 2003 Sep-Oct;26(5):451-60.

PMID:
12973034

Supplemental Content

Support Center